[go: up one dir, main page]

MX2009000659A - Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. - Google Patents

Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.

Info

Publication number
MX2009000659A
MX2009000659A MX2009000659A MX2009000659A MX2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A
Authority
MX
Mexico
Prior art keywords
methods
present
herv
immune response
immunogenic compositions
Prior art date
Application number
MX2009000659A
Other languages
English (en)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2009000659A publication Critical patent/MX2009000659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona polipéptidos de HERV aislados, y composiciones que contienen un polipéptido de HERV. La presente invención proporciona composiciones inmunógenas que contienen un ácido nucleico que incluye una secuencia de nucleótidos que codifica un polipéptido de HERV. Las composiciones inmunógenas son útiles para estimular una respuesta inmunitaria en una célula T a un péptido lentiviral. La presente invención también proporciona métodos para tratar cánceres en los cuales se expresan polipéptidos de HERV. También se proporcionan métodos para tratar trastornos que involucran la disminución de una respuesta inmunitaria a un polipéptido HERV.
MX2009000659A 2006-07-21 2007-07-19 Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. MX2009000659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
PCT/US2007/016403 WO2008011120A2 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009000659A true MX2009000659A (es) 2009-06-08

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000659A MX2009000659A (es) 2006-07-21 2007-07-19 Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.

Country Status (15)

Country Link
US (2) US20080171061A1 (es)
EP (1) EP2046380A4 (es)
JP (1) JP2009544614A (es)
KR (1) KR20090060410A (es)
CN (1) CN101557823A (es)
AU (1) AU2007275693A1 (es)
BR (1) BRPI0714714A2 (es)
CA (1) CA2658393A1 (es)
IL (1) IL196516A0 (es)
MX (1) MX2009000659A (es)
NO (1) NO20090818L (es)
RU (1) RU2009106089A (es)
SG (1) SG173997A1 (es)
WO (1) WO2008011120A2 (es)
ZA (1) ZA200900379B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
JP5504163B2 (ja) * 2008-09-18 2014-05-28 学校法人慶應義塾 がんの診断方法と治療方法
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
JP6073031B2 (ja) * 2009-12-28 2017-02-01 タケダ ヴァクシーンズ， インコーポレイテッド インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US8785492B2 (en) 2012-01-26 2014-07-22 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
NZ749585A (en) 2016-06-30 2023-02-24 Us Health Herv-e reactive t cell receptors and methods of use
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
EP4450516A3 (en) * 2017-09-01 2025-01-22 InProTher ApS A vaccine for use in the prophylaxis and/or treatment of a disease
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
EP3846839A1 (en) * 2018-09-06 2021-07-14 Centre Léon Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
CA3143327A1 (en) 2019-06-13 2020-12-17 J. Keith Joung Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
JP2023535726A (ja) 2020-07-24 2023-08-21 ザ ジェネラル ホスピタル コーポレイション 増強ウイルス様粒子および細胞への送達のためのその使用方法
US20240189247A1 (en) * 2022-11-16 2024-06-13 The General Hospital Corporation Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2002338856A1 (en) * 2001-09-06 2003-03-24 Novimmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
WO2003050258A2 (en) * 2001-12-07 2003-06-19 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
US20080171061A1 (en) 2008-07-17
WO2008011120A2 (en) 2008-01-24
CA2658393A1 (en) 2008-01-24
KR20090060410A (ko) 2009-06-12
EP2046380A4 (en) 2013-05-01
RU2009106089A (ru) 2010-08-27
CN101557823A (zh) 2009-10-14
US20130323279A1 (en) 2013-12-05
EP2046380A2 (en) 2009-04-15
IL196516A0 (en) 2011-08-01
BRPI0714714A2 (pt) 2013-04-09
WO2008011120A3 (en) 2008-11-06
JP2009544614A (ja) 2009-12-17
NO20090818L (no) 2009-04-17
AU2007275693A1 (en) 2008-01-24
ZA200900379B (en) 2010-08-25
SG173997A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
MX2009000659A (es) Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.
WO2009038756A3 (en) Long interspersed nuclear element polypeptide compositions and methods of use thereof
PH12012502272A1 (en) Biological materials related to her3
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2470559A4 (en) COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM
WO2006103666A3 (en) Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
PH12012501613A1 (en) Agonist dr5 binding polypeptides
MY177065A (en) 4-1bb binding molecules
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
IN2012DN02981A (es)
TN2012000167A1 (en) Human il-23 antigen binding proteins
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MY180564A (en) Human cgrp receptor binding proteins
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
NZ706884A (en) Fc gamma receptor iib variants
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
MX2010009071A (es) Peptidos aislados que tienen actividad inhibitoria de fosfolipasa.
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
GB201018125D0 (en) Peptide

Legal Events

Date Code Title Description
FA Abandonment or withdrawal